Our results not only confirm that PIK3CA mutant tumors are sensitive to treatment with PI3K/mTOR inhibitors but also further elucidate the ability of PI3K/mTOR inhibitors to target mutant CSCs in colorectal cancer. This evidence concerns the gene PIK3CA and colorectal cancer.